Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study
Technology in Cancer Research & Treatment · 2023
DOI: 10.1177/15330338231154088 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Technology in Cancer Research & Treatment, 2023. Verfasst von Valérie Fonteyne und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy and Oncology, 60200Ghent University Hospital, Ghent, Belgium. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiotherapy, Intensity-Modulated. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ipsen.
Abstract (Originalsprache)
Objectives
The aim is to evaluate the incidental dose to the lymphatic regions in prostate-only radiotherapy (PORT) and to compare hematological outcome between PORT and whole pelvic radiotherapy (WPRT) in node-positive prostate cancer (pN1 PCa), in the era of modern radiotherapy techniques.
Methods
We performed a prospective phase 3 trial in which a total of 64 pN1 PCa patients were randomized between PORT (ARM A) and WPRT (ARM B) delivered with volumetric-modulated arc therapy (VMAT). The lymph node (LN) regions were delineated separately and differences between groups were calculated using Welch t-tests. Hematological toxicity was scored according to common terminology criteria for adverse events (CTCAE) version 4.03. To evaluate differences in the evolution of red blood cell (RBC), white blood cell (WBC), and platelet count over time between PORT and WPRT, 3 linear mixed models with a random intercept for the patient was fit with model terms randomization group, study time point, and the interaction between both categorical predictors.
Results
Except for dose to the obturator region, the incidental dose to the surrounding LN areas was low in ARM A. None of the patients developed severe hematological toxicity. The change in RBC from time point pre-external beam radiotherapy (EBRT) to month 3 and for WBC from time point pre-EBRT to months 3 and 12 was significantly different with ARM B showing a larger decrease.
Conclusion
The incidental dose to the lymphatic areas becomes neglectable when PORT is delivered with VMAT. Hematological toxicity is very low after WPRT with VMAT and when bone marrow constraints are used for planning, although WPRT causes a decrease in RBC and WBC count over time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiotherapy and Oncology, 60200Ghent University Hospital, Ghent, Belgium.
- Department of Human structure and Repair, 26656Ghent University, Ghent, Belgium.
- Department of Radiotherapy and Oncology, University Hospitals Leuven, Louvain, Belgium.
- Department of Radiotherapy and Oncology, 60211AZ Groeninge, Kortrijk, Belgium.
- Department of Medicine and Health Science, 26656Ghent University, Ghent, Belgium.
ORCID-Profile: Valérie Fonteyne, Steven Wallaert
Förderung
- Ipsen
Zitieren
APA
Fonteyne, V., Danckaert, W., Ost, P., Berghen, C., Vandecasteele, K., Vanneste, B., Rans, K., Liefhooghe, N., Wallaert, S., & Paelinck, L. (2023). Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338231154088
Vancouver
Fonteyne V, Danckaert W, Ost P, Berghen C, Vandecasteele K, Vanneste B, et al. Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study. Technology in Cancer Research & Treatment. 2023. doi:10.1177/15330338231154088
BibTeX
@article{Fonteyne2023,
author = {Fonteyne, Valérie and Danckaert, Willeke and Ost, Piet and Berghen, Charlien and Vandecasteele, Katrien and Vanneste, Ben and Rans, Kato and Liefhooghe, Nick and Wallaert, Steven and Paelinck, Leen},
title = {Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study},
journal = {Technology in Cancer Research & Treatment},
year = {2023},
doi = {10.1177/15330338231154088}
}
EUVIMED